1. Home
  2. Publications
  3. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.

Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.

Cai, Xuezhu, Vyshak Chandra, Yangming Ou, Kyrre Emblem, Alona Muzikansky, John Evans, Jayashree Kalpathy-Cramer, et al. 2015. “Phase II Study of Tivozanib, an Oral VEGFR Inhibitor, in Patients With Recurrent Glioblastoma..”
Last updated on 02/27/2023